Skip to content

13F-HR filed by GREAT POINT PARTNERS LLC

GREAT POINT PARTNERS LLC filed this 13F-HR for the quarter ended 2016-03-31, filed 2016-05-16, with 33 holding rows worth $278,668,000.

Accession
0000930413-16-007144
Filed
2016-05-16
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q1 2016

A holdings report, 33 entries on the cover page, a total value of $278,668,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $278,668,000 with VALUE read as thousands by filing date, 13F file number 028-11743. The quarter's positions are built on this report. The resolved quarter.

Other managers

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
ADAMAS PHARMACEUTICALS INC00548A106COM2,109,099$30,498,000thousands by filing date
FIVE PRIME THERAPEUTICS INC.33830X104Common Stock575,000$23,362,000thousands by filing date
VANDA PHARMACEUTICALS INC921659108COM2,731,210$22,833,000thousands by filing date
ZOGENIX INC.98978L204Common Stock2,085,959$19,274,000thousands by filing date
TETRAPHASE PHARMACEUTICALS INC88165N105COMMON STOCK3,653,200$16,914,000thousands by filing date
BLUEBIRD BIO INC09609G100COM393,135$16,708,000thousands by filing date
EXELIXIS INC COM30161Q104Stock3,896,113$15,584,000thousands by filing date
NEUROCRINE BIOSCIENCES INC64125C109COM325,300$12,866,000thousands by filing date
INTERCEPT PHARMACEUTICALS IN45845P108COM100,000$12,847,000thousands by filing dateput
VERICEL CORP92346J108COM2,110,738$12,369,000thousands by filing date
CONNECTURE INC COM20786J106Stock4,127,232$10,566,000thousands by filing date
Alcobra LtdM2239P109SHS2,020,166$7,656,000thousands by filing date
AURINIA PHARMACEUTICALS INC COM05156V102Stock2,457,144$7,187,000thousands by filing date
XENCOR INC98401F105COMMON STOCK528,692$7,095,000thousands by filing date
AVALANCHE BIOT05337G107Common Stock1,295,416$6,697,000thousands by filing date
CHIMERIX INC COM16934W106Stock1,300,000$6,643,000thousands by filing date
RAPTOR PHARMACEUTICAL CORP75382F106COM1,346,344$6,193,000thousands by filing date
SYNERGY PHARMACEUTICALS DEL871639308COM NEW2,175,000$6,003,000thousands by filing date
OCERA THERAPEUTICS INC COM67552A108COM1,963,777$5,774,000thousands by filing date
PARATEK PHARMACEUTICALS INC699374302Equity305,459$4,634,000thousands by filing date
BOVIE MEDICAL CORP10211F100COM2,680,000$4,476,000thousands by filing date
SUNESIS PHARMACEUTICALS INC867328601COM NEW8,250,000$4,455,000thousands by filing date
ARADIGM CORP038505400COM NO PAR NEW1,002,962$4,453,000thousands by filing date
SAREPTA THERAPEUTICS INC803607100COM150,000$2,928,000thousands by filing datecall
ACADIA PHARMACEUTICALS INC004225108COM100,000$2,796,000thousands by filing date
TENAX THERAPEUTICS INC88032L100COM1,108,593$2,273,000thousands by filing date
IGNYTA INC451731103COM287,173$1,944,000thousands by filing date
CALADRIUS BIOSCIENCES INC128058104Cmn1,710,600$1,283,000thousands by filing date
PORTOLA PHARMACEUTICALS INC COM737010108Stock50,000$1,020,000thousands by filing date
PORTOLA PHARMACEUTICALS INC COM737010108Stock29,300$598,000thousands by filing datecall
RIGEL PHARMACEUTICALS INC766559603COMMON STOCK157,872$328,000thousands by filing date
STREAMLINE HEALTH SOLUTIONS86323X106COM151,611$214,000thousands by filing date
ATYR PHARMA INC002120103COM49,906$197,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0000930413-16-007144this filing2016-05-16acceptance time not in the bulk data set